- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00815347
Bosentan for Poorly Controlled Asthma
The Effect of the ET-1 Receptor Antagonist, Bosentan on Patients With Poorly Controlled Asthma-A 17 Week, Double-blind, Placebo Controlled Crossover Trial
Hypothesis: The endothelin-1 receptor antagonist, bosentan when added to the treatment of asthma patients who are symptomatic despite the use of controller therapy will improve asthma symptoms and physiology.
Twenty patients with a diagnosis of asthma, between the ages of 21 and 70 who are symptomatic despite the use of at least one controller medication will be randomized to either placebo or active medication for an 8 week period (initial 4 weeks is at 1/2 of final dose as per package insert and FDA approval). Measures of lung function and symptoms will be recorded. Patients will then cross over, so that patients initially on placebo will receive active drug for 8 weeks and those initially on active drug will receive placebo. The same endpoints will be measured. The acute bronchodilator effects of the drug will also be tested on the first day of therapy at the full therapeutic dose.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030-2810
- University of Connecticut Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of asthma, maintained on a minimum of 1 anti-inflammatory/controller and daily long acting B-agonist therapy with inadequate control of symptoms. (Defined as symptoms including wheezing, chest tightness or shortness of breath occurring at least 3 times a week or requiring use of "rescue" short-acting B-agonist at least 3 times a week).
- FEV1 less than 80% of predicted and greater than 40% at screening visit.
- A minimum of 12% reversibility of FEV1 after albuterol on screening visit or previously documented during the prior two years.
- Women of childbearing potential must use 2 non-hormonal methods of birth control (2 methods between the subject and her partner) while on the study and for 1 month after the last dose of study medication.
- Male subjects must use two non hormonal methods of birth control (2 methods between the subject and his partner) while on the study and for 1 month after the last dose of study medication.
Exclusion Criteria:
- History of liver disease, clinically significant cardiac disease, renal disease or pulmonary disease other than asthma. Patients with clinically significant laboratory abnormalities of LFTs/bilirubin (AST/ALT, TBili, alkaline phosphatase) and clinically significant anemia will be excluded. Clinically significant anemia will be defined as any anemia resulting in serum Hgb more than 1 gm/dl below the LLN, Patients with isolated minimal elevations of bilirubin (eg. as occurs in Gilbert's disease) or minimal elevations in transaminases (less than 1.2 x ULN) without a history of liver disease, risk factors for liver disease or symptoms of liver disease may still be included in the study at the investigator's discretion, but will have LFT testing at each study visit.)
- Cigarette history of >10 pack years.
- Predicted inability to adhere to medication regimen or documentation requirements of the study (symptom and medication diaries).
- Respiratory infection during 30 days preceding screening visit.
- Requirement for change in scheduled asthma medication use, including oral steroid dose change, or acute medical care for asthma during the 30 days preceding screening visit.
- Predicted inability to safely refrain from B-agonist use for the required amount of time on study visit days.
- Use of tiotropium
- Pregnancy, breast feeding or the use of hormonal methods of birth control as the only means of birth control during the study.
- Use of potent CYP3A4 and CYP2C9 inhibitors, including, but not limited to azole antifungals, amiodarone, glyburide, warfarin, cyclosporine, ritonavir, other medications potentially toxic to the liver or bone marrow.
- Use of any illegal drugs or alcohol abuse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 1 Crossover
|
Bosentan 62.5mg or placebo orally, twice a day for four weeks.
After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks.
At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
Bosentan 62.5mg or placebo orally, twice a day for four weeks.
After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks.
At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in FEV1
Time Frame: 1, 2, 4 hours after dosing
|
1, 2, 4 hours after dosing
|
|
Peak Flow
Time Frame: last 7 days of each dosing period
|
last 7 days of each dosing period
|
|
Symptom Scores
Time Frame: Last 7 days of each dosing period
|
Symptom score could range from a minimum of 7 (no symptoms) to 35 (severe symptoms)
|
Last 7 days of each dosing period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FEV1
Time Frame: end of dosing period
|
end of dosing period
|
|
Rescue Beta-agonist
Time Frame: end of each dosing period
|
end of each dosing period
|
|
Asthma Control Test Questionnaire
Time Frame: end of each dosing period
|
Patient reported outcome minimum 5 (no symptoms) maximum 25 (severe symptoms)
|
end of each dosing period
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Requirement for Escalation of Controller Medication.
Time Frame: 17 weeks
|
17 weeks
|
Requirement for Urgent Medical Care for Asthma.
Time Frame: 17 weeks
|
17 weeks
|
Ability to Taper Systemic Steroids Among Those Patients Who Are on Systemic Steroids at Study Entry.
Time Frame: 17 weeks
|
17 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark L Metersky, MD, UConn Health
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Endothelin Receptor Antagonists
- Bosentan
Other Study ID Numbers
- 08-287-1
- 001 (NavyGHB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on bosentan
-
ActelionCompletedDigital UlcersFrance, United Kingdom, United States, Austria, Canada, Germany, Italy, Switzerland
-
GeropharmCompletedBioequivalenceRussian Federation
-
ActelionCompletedSystemic Sclerosis | Digital UlcersUnited States, Canada
-
ActelionCompletedPulmonary Arterial Hypertension Related to Eisenmenger PhysiologyCanada, United Kingdom, Italy, United States, Netherlands, Australia, Austria, Belgium, France, Germany, Spain
-
ActelionCompletedPulmonary HypertensionUnited States, Canada, Australia, Germany, Italy, United Kingdom, France, Austria, Belgium, Czech Republic, Netherlands, Poland, Spain
-
Medical University of ViennaCompletedGlaucoma | Blood Flow VelocityAustria
-
ActelionCompletedInterstitial Lung Disease | SclerodermaUnited States, Korea, Republic of, Israel, France, United Kingdom, Netherlands, Switzerland, Germany, Canada, Italy, Sweden
-
General Hospital of ChalkidaUnknownSECONDARY PULMONARY HYPERTENSION | MITRAL STENOSIS | CHILDHOOD RHEUMATOID FEVER | CONGESTIVE HEART FAILUREGreece
-
Rikshospitalet University HospitalTerminated
-
Rajan SaggarActelionWithdrawnIdiopathic Pulmonary Fibrosis | Pulmonary Arterial HypertensionUnited States